Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

被引：101

作者：

Menet, Christel J. ^{[1
]}

Fletcher, Stephen R. ^{[2
]}

Van Lommen, Guy ^{[1
]}

Geney, Raphael ^{[3
]}

Blanc, Javier ^{[1
]}

Smits, Koen ^{[1
]}

Jouannigot, Nolwenn ^{[1
]}

Deprez, Pierre ^{[3
]}

van der Aar, Ellen M. ^{[1
]}

Clement-Lacroix, Philippe ^{[3
]}

Lepescheux, Lien ^{[3
]}

Galien, Rene ^{[3
]}

Vayssiere, Beatrice ^{[3
]}

Nelles, Luc ^{[1
]}

Christophe, Thierry ^{[1
]}

Brys, Reginald ^{[1
]}

Uhring, Muriel ^{[4
]}

Ciesieski, Fabrice ^{[4
]}

Van Rompaey, Luc ^{[1
]}

机构：

[1] Galapagos NV, B-2800 Mechelen, Belgium

[2] BioFocus, Saffron Walden CB10 1XL, Essex, England

[3] Galapagos SASU, F-93230 Romainville, France

[4] NovAliX, F-67405 Illkirch Graffenstaden, France

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2014年 / 57卷 / 22期

关键词：

INFLAMMATORY DISEASES; RHEUMATOID-ARTHRITIS; CYTOKINE RECEPTORS; RESTRICTED ROLE; DISCOVERY; RESPONSES; POTENT;

D O I：

10.1021/jm501262q

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohns disease (CD).

引用

页码：9323 / 9342

页数：20

共 50 条

[31] SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL
Vanhoutte, F. P.
Van der Aa, A.
Meuleners, L.
van 't Klooster, G.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 242 - 242
[32] DOSE SELECTION OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, FOR RHEUMATOID ARTHRITIS PHASE 2B STUDIES: PK/PD AND EXPOSURE-DAS28 MODELING APPROACH
Namour, F.
Tasset, C.
van't Klooster, G.
Diderichsen, P. M.
Cox, E.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 220 - 221
[33] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
Vermeire, Severine
Schreiber, Stefan
Petryka, Robert
Kuehbacher, Tanja
Hebuterne, Xavier
Roblin, Xavier
Klopocka, Maria
Goldis, Adrian
Wisniewska-Jarosinska, Maria A.
Baranovsky, Andrei
Sike, Robert
Tasset, Chantal T.
Van der Aa, Annegret
Harrison, Pille
GASTROENTEROLOGY, 2016, 150 (04) : S1267 - S1267
[34] Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach.
Namour, Florence
Tasset, Chantal
Vayssierre, Beatrice
van 't Klooster, Gerben
Diderichsen, Paul
Cox, Eugene
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S650 - S651
[35] Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Kavanaugh, A.
Kremer, J.
Ponce, L.
Cseuz, R.
Reshetko, O. V.
Stanislavchuk, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1009 - 1019
[36] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
Kavanaugh, A.
Ponce, L.
Cseuz, R.
Reshetko, O.
Stanislavchuk, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
[37] THE EFFECT OF FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR ON PATIENT-REPORTED OUTCOMES: RESULTS FROM TWO 24-WEEK PHASE 2B DOSE RANGING STUDIES
Genovese, M.
Westhovens, R.
Kavanaugh, A.
Meuleners, L.
Van der Aa, A.
Harrison, P.
Tasset, C.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 244 - 244
[38] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
Westhovens, R.
Alten, R.
Pavlova, D.
Sosa, F. E. Enriquez
Mazur, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
[39] Identification of selective JAK1 inhibitors for treatment of autoimmune diseases
Kaila, Neelu
Vazquez, Michael
Unwalla, Rayomand
Strohbach, Joseph
Trzupek, John
Han, Seungil
Robinson, Ralph
Parikh, Mihir
Arnold, Eric
Choi, Chulho
Drozda, Susan
Dowty, Martin
Telliez, Jean-Baptiste
Hegen, Martin
Symanowicz, Peter
Jussif, Jason
Radi, Zaher
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[40] 4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
Galien, Rene
Harrison, Pille
Brys, Reginald
Van der Aa, Annegret
van't Klooster, Gerben
Tasset, Chantal
ARTHRITIS & RHEUMATOLOGY, 2015, 67

← 1 2 3 4 5 →